A review of the last decade: pancreatic cancer and type 2 diabetes

AbstractPancreatic cancer (PC) is a prevalent gastrointestinal tumour known for its high degree of malignancy, resulting in a mere 10% five-year survival rate for most patients. Over the past decade, a growing body of research has shed light on the intricate bidirectional association between PC and Type 2 diabetes (T2DM). The collection of PC- and T2DM-related articles is derived from two comprehensive databases, namely WOS (Web of Science Core Collection) and CNKI (China National Knowledge Infrastructure). This article discusses the last 10 years of research trends in PC and T2DM and explores their potential regulatory relationship as well as related medications.Keywords: Pancreatic cancertype 2 diabetesrelationship10 yearsdrugs AcknowledgementsGratitude to all diabetes and pancreatic cancer researchers, as well as the Human Protein Atlas for providing materials and data. Additionally, thanks to the developers of “Bibliometrix” and “VOSviewer” software for their contributions. Lastly, appreciation to Ashling from Otago Girls’ High School for the insightful discussion of the article.Authors’ contributionsLL and JQW completed the drawing of the picture and the writing of part of the content. FZ and XC reviewed and checked the full text. LL, XC, and LT conceived and supervised the writing of this article.Disclosure statementAuthors declare no conflict of interests for this article.Consent for publicationAll the authors have approved the manuscript.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.